Immune system

The Kia EV9 powers a light installation to mimic the sun in Norway

Retrieved on: 
Friday, February 23, 2024

"The EV9 is exciting when moving, but also when stationary with innovative features such as bidirectional charging," said David Hilbert, Head of Marketing, Kia Europe.

Key Points: 
  • "The EV9 is exciting when moving, but also when stationary with innovative features such as bidirectional charging," said David Hilbert, Head of Marketing, Kia Europe.
  • The light installation was set up in Rampton, a campground on a fjord 35 kilometres southwest of Oslo.
  • The EV9 was able to drive from Oslo to Rampton, power the light for twenty-four hours, and then return to Oslo without range anxiety.
  • Built on the Electric Global Modular Platform, the EV9 ensures athletic performance and an all-electric range of more than 563 km.

The Kia EV9 powers a light installation to mimic the sun in Norway

Retrieved on: 
Friday, February 23, 2024

"The EV9 is exciting when moving, but also when stationary with innovative features such as bidirectional charging," said David Hilbert, Head of Marketing, Kia Europe.

Key Points: 
  • "The EV9 is exciting when moving, but also when stationary with innovative features such as bidirectional charging," said David Hilbert, Head of Marketing, Kia Europe.
  • The light installation was set up in Rampton, a campground on a fjord 35 kilometres southwest of Oslo.
  • The EV9 was able to drive from Oslo to Rampton, power the light for twenty-four hours, and then return to Oslo without range anxiety.
  • Built on the Electric Global Modular Platform, the EV9 ensures athletic performance and an all-electric range of more than 563 km.

Limmi adds Oncobiomix as customer of Disease Insights Platform, powering microbiome-based risk prediction for cancer

Retrieved on: 
Tuesday, February 20, 2024

"Our partnership with Limmi combined with our revolutionary microbiome risk prediction biomarker is poised to transform how we think about cancer risk, starting with prostate cancer."

Key Points: 
  • "Our partnership with Limmi combined with our revolutionary microbiome risk prediction biomarker is poised to transform how we think about cancer risk, starting with prostate cancer."
  • Oncobiomix will use Limmi's Disease Insights Platform to power their AI models for predicting prostate cancer risk.
  • The platform will be used to trained additional improved models for prostate cancer risk as well as other cancer risk profiles as Oncobiomix adds new IP to their portfolio of risk detection diagnostics.
  • "We are proud to help Oncobiomix enhance microbiome-based disease risk predictions, by sifting through the large genetic datasets and providing new AI models and insights that continuously learn and improve over time."

Allergy Breakthrough - New Study Reveals Unique Prebiotic AllerPops® Offer Long-Term Allergy Relief

Retrieved on: 
Tuesday, February 20, 2024

LOS ALAMOS, N.M., Feb. 20, 2024 /PRNewswire/ -- In a completely novel approach to allergy care, AllerPops recently offered groundbreaking data that charts a new course in all-natural allergy relief. Published this year and available online at the NIH's National Library of Medicine, the paper showcases the significant effects of AllerPops prebiotic lollipops in providing sustained allergy relief, via the restoration of oral probiotic balance.

Key Points: 
  • LOS ALAMOS, N.M., Feb. 20, 2024 /PRNewswire/ -- In a completely novel approach to allergy care, AllerPops recently offered groundbreaking data that charts a new course in all-natural allergy relief.
  • Published this year and available online at the NIH's National Library of Medicine , the paper showcases the significant effects of AllerPops prebiotic lollipops in providing sustained allergy relief, via the restoration of oral probiotic balance.
  • "These results not only validate our approach but also pave the way for the national debut of our products.
  • Sustained Relief: Participants in the investigational group experienced significant allergy relief (P = 0.002), showcasing AllerPops' effectiveness over traditional remedies.

Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection

Retrieved on: 
Monday, February 19, 2024

Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).

Key Points: 
  • Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).
  • APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old.
  • It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.
  • The effects of Bcc vary widely, ranging from no symptoms at all to serious infections.

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Tuesday, March 5, 2024

BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.

Key Points: 
  • BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
  • The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
  • "Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
  • "We are committed to supporting Transgene and NEC as they advance these clinical trials," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma

Retrieved on: 
Friday, February 16, 2024

WASHINGTON, Feb. 16, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics' AMTAGVI™ (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.

Key Points: 
  • WASHINGTON, Feb. 16, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics' AMTAGVI™ (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.
  • AMTAGVI is the first individualized Tumor Infiltrating Lymphocyte (TIL) therapy to earn FDA approval for any cancer.
  • After the TIL infusion, patients are treated with a therapy that stimulates the immune system to grow and divide.
  • "This groundbreaking T-cell immunotherapy represents a significant advancement in our ability to combat melanoma," says MRA Chief Executive Officer Marc Hurlbert, PhD.

Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

Retrieved on: 
Friday, February 16, 2024

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response. Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit.

Key Points: 
  • This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response.
  • AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer.
  • “Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients.
  • Iovance will host a conference call and live audio webcast today to discuss the FDA approval of AMTAGVI.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Friday, February 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

MOJO Health Expands Personalized Holistic Health and Cancer Care Offerings with High-Quality Supplement Shop

Retrieved on: 
Friday, February 16, 2024

ATLANTA, Feb. 16, 2024 /PRNewswire-PRWeb/ -- MOJO Health is proud to announce the launch of its personalized high-quality supplement shop, furthering its mission to make holistic healthcare accessible to all and to evolve the cancer healing process to include the best of both conventional and traditional healing methodologies. Acknowledging the importance of supplement quality, MOJO Health has done the legwork for individuals facing cancer or serious diagnoses even beyond cancer to find the best in-kind supplements to increase their overall health and to learn how to potentially outmaneuver side effects.

Key Points: 
  • Acknowledging the importance of supplement quality, MOJO Health has done the legwork for individuals facing cancer or serious diagnoses even beyond cancer to find the best in-kind supplements to increase their overall health and to learn how to potentially outmaneuver side effects.
  • "I've worked with hundreds of cancer patients and can say unequivocally that patients who start with stronger vitality weather health challenge storms with much fewer headwinds," says Oscar Sierra, Chief Health Officer of MOJO Health.
  • The MOJO supplement shop follows the launch of MOJO Health's successful introduction of the holistic care Strategy Builder - a new-in-kind tool that empowers individuals facing cancer and side effects beyond cancer to create a personalized holistic strategy plan, in addition to their prescribed conventional treatment approach.
  • "I've worked with hundreds of cancer patients and can say unequivocally that patients who start with stronger vitality weather health challenge storms with much fewer headwinds," says Oscar Sierra, Chief Health Officer of MOJO Health.